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Abstract
Objective: Exercise may be physically and psychologically important for people
with ALS, especially in the earlier stages of the disease, and, as a consequence,
current ALS clinical management includes individualized rehabilitation as part
of multidisciplinary care because. However, while recent studies focused on
which type of exercise is more indicated to ALS patients, there is no evidence
at which frequency training sessions should be performed. Methods: We per-
formed an assessor blinded randomized clinical trial to investigate the superior-
ity of two different frequencies of exercise on rate of progression in ALS. We
enrolled 65 patients in two groups: intensive exercise regimen (IER, five ses-
sions/week) versus usual exercise regimen (UER, two sessions/week). The pri-
mary aim was to assess if IER decreased disease progression, measured through
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, with respect to
UER. Secondary aims included assessment of adverse events, tracheostomy-free
survival, motor and respiratory functions, fatigue, quality of life and caregiver
burden. Treatment regimen consisted for both groups of the same kind of exer-
cise including aerobic training, endurance training, stretching or assisted active
mobilization, differing for frequency of intervention. Results: No significant
changes in disease progression were found in patients under IER versus UER.
At the end of the study, there were no significant differences between the two
groups in survival, respiratory function, time to supporting procedures, and
quality of life. Adverse events, fatigue, and caregiver burden were not different
between the two treatment regimens. Conclusions: Despite some limitations,
our trial demonstrated that high-frequency physical exercise was not superior
to UER on ALSFRS-R scores, motor and respiratory functions, survival, fatigue,
and quality of life of ALS patients.
Introduction
Amyotrophic lateral sclerosis (ALS) is a relentless progres-
sive neurodegenerative disease with severe prognosis due
to the mounting muscle atrophy and weakness later
impending on muscles of respiration and swallowing; on
average, death occurs within 3 years from diagnosis.1
Despite intensive research, to date, the only FDA-
approved drugs for ALS are Riluzole, which proved effec-
tive in increasing survival by 3–6 months2 and Edaravone,
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the newly approved and controversial antioxidant with
demonstrated slowing of progression in a subgroup of
patients.3
Nonetheless, the several advancements made in the
field of clinical patients’ management, multidisciplinary
approach, and decision-making processes result in life
prolongation for ALS patients.4
During the disease course, as a consequence of the
spread and progression of muscle atrophy, cardiorespira-
tory deconditioning and disuse weakness ensue, which
further precipitate the decreased possible motor activities,
leading to inactivity. The resulting decreased strength of
ligaments and tendons, joint tightness, osteoporosis, and
further muscle atrophy often lead to obliged postures and
subsequent pain and contractures, as well as psychological
drawbacks on the patient and their caregivers.5
To prevent this loop of deconditioning and improve
well-being, physical exercise is offered by physiatrists and
physical therapists in the setting of integrated multidisci-
plinary care. In healthy people, exercise allows for myofi-
bers remodeling, antioxidant and anti-inflammatory
adaptation, neural plasticity, and overall positive cardio-
vascular, respiratory, musculoskeletal, metabolic and
neuro-endocrine effects, not to mention a reinforcement
effect on psychological well-being.6 Exercise may be physi-
cally and psychologically important for people with ALS
too, especially in the earlier stages of the disease and before
significant muscular atrophy or deconditioning occurs.5
However, there is no clear evidence on which type of
exercise, under which regimen and which outcome vari-
ables have to be routinely assessed in order to bring for-
ward a safe and consistent motor rehabilitation, avoiding
muscle overuse in a disease where muscles are already
denervated and weakened.5,6
There are few randomized controlled studies on the
effect of motor rehabilitation on ALS patients with lack
of robust and consistent results.5,7,8 Moreover, while those
previous studies have focused on which type of exercise
modality is more suitable for ALS rehabilitation, the opti-
mal frequency of intervention to be recommended for
these patients has never been investigated.
On the other hand, in other clinical conditions high-
frequency exercise showed to be effective in maintaining
muscle function and improving physical function, psycho-
logical distress and quality of life (QOL).9,10
Since we could not exclude the exercise modality
(whether stretching, aerobic or resistance) or the weekly
frequency at which a motor program is established may
have mixed effects on ALS disease outcomes and patients
safety, we carried out this multicentre, single-blind,
randomized, controlled study testing the impact of an
intensive physical therapy regimen, represented by higher-
frequency sessions but equal range of exercise compared
to the “standard” motor rehabilitation regimen offered to
ALS patients.
Methods
Study design and participants
We measured the effects of motor rehabilitation under
intensive exercise regimen (IER) compared to the usual
exercise regimen (UER) in ALS patients in a single-
blinded, randomized controlled study (RCT).
Three Italian ALS multidisciplinary centers (ALS Centre
in Modena, Reggio Emilia, and Ferrara) participated in
this study providing a 10 weeks long motor-rehabilitation
program according to the allocation group, with long fol-
low-up period for a total trial duration of 24 months.
Patients with a definite, probable or possible diagnosis
of ALS according to El Escorial criteria with a clinical
diagnosis within 18 months and aged between 18 and
86 years were considered eligible unless cognitive decline,
respiratory deficit (measured by forced vital capacity
(FVC) which had to be > 50%), or other (neurological or
cardiorespiratory) conditions were present. Exclusion cri-
teria were as follows: participation in other clinical trials
within in the 3 months before screening, non-invasive
(NIV) or invasive ventilation (IV), other neurodegenera-
tive diseases, severe or instable medical conditions con-
traindicating rehabilitation treatment, pregnancy or
breeding, residency outside Emilia Romagna Region,
absence of multidisciplinary follow up.
Trial registration
The trial was identified on ClinicalTrials.gov with
NCT02306109. After approval from Ethics Committees of
Modena, Reggio Emilia and Ferrara, patients were
enrolled once provided signed written consent in accor-
dance to the declaration of Helsinki.
Intervention
Eligible patients were randomized with 1:1 allocation to
IER or to UER. Each exercise program had to be com-
posed of a mixture of aerobic, endurance, and low-load
resistive training associated with stretching of retracted
muscles as explicated in Table 1.
Standard operating procedures on motor rehabilitation
were created and shared among physiatrists. The training
was 45 min long independently of the IER or UER group;
patients randomized to IER had to undergo five trainings
per week, for 10 weeks of treatment period (50 trainings
in total), whereas patients in UER continued with two
trainings per week. After the treatment period, patients
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and trained caregivers maintained their exercise program
(IER or UER) by their own with regular supervision of a
physiotherapist once a month until month 12. Clinical
follow up was then carried out until month 24 (Fig. 1).
Primary and secondary outcomes
The primary outcome was represented by the change in
disease progression as measured by ALSFRS-R from base-
line to month 12 in patients treated with IER compared
to UER.
Secondary outcomes of the study were represented by
comparison between IER and UER arms of the following:
I) disease progression as measured by changes in ALSFRS-
R scale every 3 months; II) survival; III) time to gastros-
tomy, NIV or IV; IV) respiratory function as measured by
FVC% every 3 months; V) quality of life (assessed by
ALSAQ-40 and McGill Quality of Life Questionnaire),
every 6 months; VI) fatigue (assessed by fatigue severity
scale (FSS)) every 6 months; VII) depression (Beck inven-
tory scale), every 6 months; VIII) burden on caregiver
(assessed by caregiver burden scale) every 6 months.
Assessments
Regular assessments were done by the neurologist and
physiatrist in parallel during the treatment and follow-up
period. The neurologist performed basal evaluations of
the patients, which included ALSFRS-R, MRC, spirome-
try, evaluation of quality of life, fatigue and depression as
aforementioned before treatment phase. The neurologist
was blinded to the allocation group and visited the
patient every 3 months until the 24th month, performing
ALSFRS-R, MRC, and spirometry. ALSAQ-40, FSS, Beck
inventory scale, and caregiver burden scale were re-
assessed by the neurologist every 6 months. Physiothera-
pist and physiatrist in charge of each individualized
motor program were not obviously blind to the treatment
arm. Motor programs were revised during the follow-up
period by the combined re-evaluations performed by the
physiotherapist, who re-assessed the patient monthly, and
by the physiatrist who visited the patient every 3 months.
Sample size
Sample size was calculated considering as primary end-
point the difference of at least four points in the
ALSFRS-R at 12 months, favoring the IER group to the
UER. It has been reported that ALS caring neurologists
consider of clinically significance a difference of four
points in the decline of ALSFRS-R.11 Assuming an aver-
age decline in ALSFRS-R score of 1/month,12 a difference
of four points in 1 year represents a decrease in ALS
decline of the 33%.
The null hypothesis was that the mean difference in
ALSFRS-R score between the two treatment arms was < 4
Table 1. Motor program protocols in the two treatment arms.
IER (n = 32) UER (n = 33)
Frequency 5/week 2/week
Duration 45 min 45 min
Total session count 50 20
Initial evaluation MRC strength, A.R.o.M. and P.R.o.M. at elbow,
shoulder, hip, knee, and ankle. Hypertonia
evaluation by Ashworth at ankle, knee, elbow.
6MWDT.
MRC strength, A.R.o.M. and P.R.o.M. at elbow,
shoulder, hip, knee, and ankle. Hypertonia
evaluation by Ashworth at ankle, knee, elbow.
6MWDT.
Motor programs Aerobic training * patients able to walk: on treadmill or cyclette;
speed parameters are adjusted on moderate
effort (Borg scale 3); 10 min exercise followed
by 5 min break for a total of 30 min.
* patients able to walk: on treadmill or cyclette;
speed parameters are adjusted on moderate
effort (Borg scale 3); 10 min exercise followed
by 5 min break for a total of 30 min.
* patients unable to walk but with residual
strength: the same on cyclette.
* patients unable to walk but with residual
strength: the same on cyclette.
Endurance training On non-affected muscles. Resistive force is the
40% of MCV, in 12–15 repeats per 2 sets for
each movement. Tools or elastic ropes might be
used. 5 min break between sets are required. To
be done at least at 3 or more sessions.
On non-affected muscles. Resistive force is the
40% of MCV, in 12–15 repeats per 2 sets for
each movement. Tools or elastic ropes might be
used. 5 min break between sets are required. To
be done at each session.
Stretching or assisted
active mobilization
Programs can be of short, middle or long
duration; to be applied at each training session
Programs can be of short, middle or long
duration for both sessions
IER, intensive exercise regimen; UER, usual exercise regimen; MRC, Medical Research Council Muscle Scale; ARoM, Active Range of Motion;
PRoM, Passive Range of Motion; MCV, Muscle Contraction Velocity; 6MWDT, 6-minute walk distance test.
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points at month 12 from baseline. The alternative hypoth-
esis was that IER determined a decrease in ALS decline by
at least four points in 12 months.
The study has been designed to reject the null hypothesis
with an alpha error of 0.05 and a power of 0.80. For this
purpose, a sample of 60 patients randomized in 2 arms
would be needed. Considering an average drop out of 5–10%,
a recruitment of 63–66 patients would be necessary.
Statistical analysis
The Epidemiological Unit of University of Modena and
Reggio Emilia performed all data analysis using STATA
15 software (Stata Inc. 2016, College Station, Texas). Sta-
tistical differences between the two treatment arms were
computed by t-tests or chi-squared test as appropriate.
Multivariable or bivariable conditional logistic regres-
sion was used to calculate relative risks.
Survival was calculated from disease onset to death or
tracheostomy. Differences in tracheostomy-free survival
(Kaplan–Meier method) between the two treatment
groups were compared using the log-rank test. Cox’s pro-
portional hazard model was used to adjust for any possi-
ble unbalanced prognostic factors. Missing data have been
handled using the last observation carried forward.
Results
Patients characteristics
Table 2 shows the characteristics of the 65 patients
enrolled in the study.
Except for one patient who withdrew during the treat-
ment phase because of an accidental fall, which did not
occur during the exercise sessions, all severe adverse
events (SAEs) were expected due to ALS course (hospital
admission due to gastrostomy, NIV, IV, progressive respi-
ratory insufficiency leading to support or death). During
the treatment phase, there were five SAEs (1 fall, 1 tra-
cheostomy, 3 deaths); during the follow-up phase
(22 months), 20 patients died and 11 patients underwent
tracheostomy.
Figure 1. Flow chart of the study.
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Effects of exercise regimen on disease
progression
ALSFRS-R at different time points during follow-up per-
iod was not significantly different across the two groups
(Fig. 2, Table 3).
Next, subscores within ALSFRS-R were analyzed to
detect if motor or respiratory domains had benefited
more of one regimen over the other (Table 3). No differ-
ences in each subscore were found.
There was no advantage in survival for IER group com-
pared to UER (Fig. 3A). Median tracheostomy-free sur-
vival from onset was 38 months for patients in IER and
35 months for patients in UER (HR 0.89, 95% CI 0.45–
1.78, P = 0.754). Multivariable analysis performed with
Cox regression model and taking into account age,
ALSFRS-R, and FVC at basal evaluation, confirmed the
lack of a prognostic role of IER/UER (HR 0.96, 95% CI
0.48–1.91, P = 0.906). Similar results were obtained con-
sidering the time from onset to PEG or NIV in the two
treatments groups (Fig. 3B,C).
Effects of exercise regimen on respiratory
function
Respiratory function was assessed by serial measurements
of FVC% (Table 4) and deterioration of the sum of respi-
ratory items score on the ALSFRS-R. No significant dif-
ference was consistently observed between the two
treatment arms at the different time points during the
follow-up period.
Effects of exercise regimen on other disease
symptoms, fatigue, and quality of life
We did not find differences in quality of life between the
two groups, as assessed by ALSAQ40 and McGill scales
every 6 months. The score of Beck’s Inventory scale for
depression assessed every 6 months was equal between the
two groups. With regard to Caregiver Burden Index, no
substantial discrepancy was noted between the two treat-
ment arms (only at the last observation the difference is
near to significance). Finally, FSS score was increased in the
IER during the last 12 months of follow-up. (Table 5).
Discussion
Our study demonstrated that there are no major changes
in ALS disease progression, as well as in survival and res-
piratory function, induced by high-frequency motor exer-
cise training of ALS patients.
The role of exercise in ALS has been intensely debated
in these years, when epidemiological studies shed different
light toward physical activity as an exogenous risk factor
for the development of the disease.13
Regardless of how exercise might have contributed to
degeneration in ALS, some studies showed exercise toler-
ance is reduced in patients as skeletal muscles’ oxygen
transport-utilization chain is impaired at different levels.14
Previous reports attributed the lowered oxygen consump-
tion to deconditioning.15
With these premises, the general principles of motor
rehabilitation for ALS patients are represented by patient
and caregivers’ education in safety and fall prevention,
strategies for energy conservation, positioning–pressure
relief techniques, and prevention of musculoskeletal pain.
This translates to environmental modifications, range of
motion exercises, functional mobility training, walking
programs, cardiopulmonary physical therapy techniques,
and strengthening exercise.16
Current clinical management for people with ALS
includes individualized rehabilitation as part of multidis-
ciplinary care, where physiotherapy and physical exercise
are considered useful.17 When modeling rehabilitation for
ALS, two main queries can guide the formulation of a
proper program6: which type of exercise (stretching, resis-
tance/strengthening, and aerobic/endurance training), and
under which regimen, based on intensity, duration, and
frequency, is more beneficial to ALS patients. In the
majority of tertiary ALS centers in Italy (where the study
was carried out), patients usually undergo physiotherapy
twice a week, in line with general recommendations for
MND patients18 and with a recent study.8
Therefore, we considered this frequency of treatment
(twice a week) as the usual regimen (UER).
Table 2. Patients characteristics at baseline.
IER (n = 32)
n (%),
mean [SD]
UER (n = 33)
n (%),
mean [SD] P value
Sex (male) 26 (81.25) 23 (69.70) 0.280
Onset (spinal) 28 (87.50) 26 (78.79) 0.349
Age at onset (years) 65.14 [9.90] 64.74 [10.10] 0.873
Disease duration at
enrollment (months)
15.67 [9.74] 16.64 [8.98] 0.677
ALSFRS-r
(total score, points)
39.84 [5.70] 40.15 [5.17] 0.820
Bulbar score (points) 11.16 [1.27] 10.70 [2.42] 0.344
Motor score (points) 17.09 [5.62] 17.084 [4.45] 0.550
Respiratory
score (points)
11.59 [0.67] 11.61 [0.79] 0.946
Disease progression
rate (points/month)
0.68 [0.49] 0.52 [0.40] 0.142
Forced vital capacity (%) 91.88 [18.98] 90.70 [17.68] 0.796
Riluzole treatment 31 (96.88) 32 (96.97) 0.982
IER, intensive exercise regimen; UER, usual exercise regimen; ALSFRS-
R, amyotrophic lateral sclerosis functional rating scale - revised.
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Figure 2. ALSFRS-R total score at different time points in patients treated with IER (A) and in patients treated with UER (B). Mean ALSFRS-R total
score at different time points in the two groups (C).
Table 3. Mean total ALSFRS-r, motor items of ALSFRS-r and respiratory items of ALSFRS-r across different time points.
Time IER (n = 32) mean, [SD] UER (n = 33) mean, [SD] P value
ALSFRS-r total score 3 months (30 vs. 28) 34.87 [8.49] 36.39 [8.01] 0.485
6 months (25 vs. 26) 33.08 [9.76] 33.08 [9.42] 0.999
9 months (22 vs. 23) 32.23 [9.15] 31.52 [9.73] 0.804
12 months (19 vs. 18) 30.16 [9.78] 28.94 [10.87] 0.723
18 months (17 vs. 11) 26.35 [10.79] 30.64 [9.53] 0.293
24 months (12 vs. 8) 27.25 [9.20] 29.00 [13.89] 0.737
ALSFRS-r motor items 3 months (30 vs. 28) 13.80 [6.05] 14.93 [6.56] 0.498
6 months (25 vs. 26) 13.20 [6.30] 13.62 [6.20] 0.813
9 months (22 vs. 23) 12.59 [6.59] 12.22 [5.79] 0.841
12 months (19 vs. 18) 11.32 [6.84] 10.89 [6.45] 0.847
18 months (17 vs. 11) 9.06 [6.61] 10.09 [6.17] 0.682
24 months (12 vs. 8) 9.58 [6.36] 10.75 [7.80] 0.718
ALSFRS-r respiratory items 3 months (30 vs. 28) 10.73 [2.68] 11.04 [1.57] 0.606
6 months (25 vs. 26) 10.36 [2.74] 9.81 [2.40] 0.447
9 months (22 vs. 23) 10.32 [2.80] 9.57 [2.83] 0.375
12 months (19 vs. 18) 9.58 [3.58] 9.28 [2.95] 0.782
18 months (17 vs. 11) 9.29 [1.75] 9.29 [3.58] 0.293
24 months (12 vs. 8) 9.33 [3.77] 10.13 [2.36] 0.605
IER, intensive exercise regimen; UER, usual exercise regimen; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale - revised.
Figure 3. Kaplan–Meyer survival curves from onset of disease to tracheostomy or death (A), to NIV (B), and to PEG (C) in patients treated with
IER compared with patients treated with UER.
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With regard to the protocol choice for the intensive
exercise regimen (IER), previous pilot randomized or
quasi-randomized clinical trials tested different modalities
of exercise even on daily basis,7,8,19–21 though they were
limited by the low number of participants and the short
follow-up period.5,19,22 In order to test a frequency closer
to that of these earlier studies, we chose five times per
week as the regimen under investigation. More recently in
these years other trials investigated which exercise modal-
ity is more indicated to ALS patients, expanding the
cohort under investigation and the duration of follow-up.
One study tested the effect of a daily strictly monitored
exercise program, further subdivided into different train-
ing modalities (resistive with and without cycloergometer,
and stretching) compared to home-based twice weekly
passive exercises, finding a reduced decline in global func-
tion in the former group as measured by ALSFRS-R but
no effects on survival, respiratory function, or QOL were
found.8
Clawson and colleagues proved there is no harmful
effect of thrice weekly resistance or endurance exercise
over stretching and range of motion when the decline of
ALSFRS-R was compared to data from PRO-ACT data-
base, the major concern being the tolerability to endur-
ance trainings.7
Another study23 evaluated the effects of a mixture of
aerobic and muscular strengthening individualized pro-
gram compared to standard neurorehabilitation protocols
for ALS patients, showing better results in terms of mus-
cle power (expressed by the MRC scale), oxygen con-
sumption (measured by VO2submax) and fatigue, not to
mention functional independence scale.
Overall, these studies confirm not only passive exercises
(range of motion and stretching) but also endurance and
Table 4. Mean FVC % across different time points in IER and UER
treated patients.
Time
IER (n = 32) FVC %
mean [SD]
UER (n = 33) FVC %
mean [SD] P value
3 months 73.83 [34.45] 79.30 [35.31] 0.560
6 months 66.24 [44.96] 77.91 [31.82] 0.308
9 months 64.36 [43.94] 64.29 [41.11] 0.995
12 months 80.88 [41.41] 74.47 [35.27] 0.647
18 months 70.79 [42.12] 65.1 [41.64] 0.746
24 months 64.33 [32.28] 65.56 [44.27] 0.942
IER, intensive exercise regimen; UER, usual exercise regimen; FVC,
forced vital capacity.
Table 5. Quality of life measures in ALS patients in the two treatment groups as measured by ALSAQ-40 and Mc Gill scales.
Time IER (n = 32) mean [SD] UER (n = 33) mean [SD] P value
ALSA-Q40 0 months (32 vs. 33) 107.25 [23.12] 105.88 [27.94] 0.830
6 months (24 vs. 24) 87.79 [39.07] 91.08 [31.44] 0.749
12 months (15 vs. 12) 76.13 [31.48] 74.92 [41.65] 0.932
18 months (15 vs. 8) 66.00 [37.10] 92.13 [42.23] 0.140
24 months (11 vs. 4) 74.64 [42.18] 99.00 [48.75] 0.358
Mc- Gill 0 months (32 vs. 33) 100.09 [24.65] 102.06 [21.97] 0.735
6 months (24 vs. 25) 86.92 [28.01] 92.92 [29.73] 0.471
12 months (15 vs. 13) 92.13 [29.70] 90.69 [31.09] 0.901
18 months (15 vs. 8) 93.93 [31.53] 94.00 [33.50] 0.996
24 months (11 vs. 4) 92.00 [28.59] 86.00 [54.34] 0.781
Beck Depression Inventory scale 0 months (32 vs. 33) 12.41 [7.22] 11.33 [8.2] 0.578
6 months (24 vs. 24) 17.17 [12.38] 14.17 [10.19] 0.364
12 months (14 vs. 11) 15.21 [10.42] 19.18 [11.57] 0.345
18 months (13 vs. 8) 18.00 [11.09] 15 [10.01] 0.540
24 months (11 vs. 4) 12.73 [7.40] 14.75 [14.31] 0.720
Caregiver Burden index 0 months (29 vs. 30) 17.41 [15.69] 13.17 [12.75] 0.258
6 months (20 vs. 21) 24.35 [17.78] 19.14 [16.23] 0.333
12 months (13 vs. 10) 29.85 [17.26] 27.30 [16.93] 0.727
18 months (13 vs. 6) 32.92 [20.40] 25.67 [15.27] 0.450
24 months (10 vs. 4) 28.90 [13.00] 13.25 [14.24] 0.070
Fatigue Severity Scale 0 months (32 vs. 32) 35.63 [15.31] 36.50 [16.53] 0.827
6 months (24 vs. 24) 41.42 [18.49] 37.38 [18.73] 0.456
12 months (15 vs. 11) 46.27 [16.25] 36.64 [19.53] 0.183
18 months (15 vs. 8) 44.13 [15.57] 30.38 [15.58] 0.056
24 months (11 vs. 4) 52.36 [11.94] 37.25 [24.58] 0.125
Beck Depression Inventory scale, Caregiver Burden Index, and Fatigue Severity Scale in the two treatment groups.
IER, intensive exercise regimen; UER, usual exercise regimen.
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moderate load resistive exercises can be applied with ben-
efits and limited side effects (such as cramps or fatigue)
to ALS patients.
The reported beneficial effect experienced by the treat-
ment arm in previous studies8,19–21 is however con-
founded by the fact that the type, frequency, and
intensity of exercise varied between the groups under
investigation, making it difficult to understand which
aspect was responsible for the benefit.
On the contrary, our study is meant to reflect standard
physical rehabilitation programs, where a mixture of exer-
cises is advised, not sticking on one modality over the
other,18 but addressing the specific question on the
advised frequency of exercise. To our knowledge, our
study is the first RCT to focus on the frequency of a
motor program.
The choice of performing all exercise modalities for the
same duration, but at different frequencies, in the two
treatment arms, removes a potential source of variability
not explored in the previous studies. The close monitor-
ing of side effects such as fatigue by continuous re-assess-
ment by physical therapist and questioning by scales
allowed us to intervene promptly in re-tailoring motor
programs.
No benefit or harm in motor or respiratory function
could be observed in the intensive regimen arm of this
trial. This on one side reassures about potential risks of
repeated exercise in ALS patients. On the other hand,
since the relevance of physical therapy is often questioned
by patients and in particular at which degree they should
insist in doing exercise at local Physical Therapy centres,
we provide evidence that twice-a-week programs are not
inferior to five times/week programs to maintain a good
functional reserve. Besides, quality of life scales were not
particularly relevant on one arm compared to the other;
it might be speculated the well-being reported in healthy
people after exercise may be outbalanced in ALS patients
by increased fatigue and disease burden. Unexpectedly,
fatigue proved to be increased under IER but only during
the second year (of follow-up), that is, after several
months from the investigated motor program. This might
be explained either by late-onset fatigue due to excess
muscle wasting in people under IER, or simply that, given
the larger proportion of IER patients still under observa-
tion at 24 months, fatigue assessment could be less accu-
rate in UER due to the little amount of patients left in
follow-up. The same reasoning may hold for the observa-
tion of raised caregiver burden in IER arm at the very
end of the follow-up period. Conversely, it is also possible
that caregiver burden in relation to IER increases with
time and diseases duration.
One limitation of the study is represented by the loss
of information during follow-up because of the high
number of dropouts due to death or tracheostomy
explained by our very long follow-up period. Neverthe-
less, the long follow-up period is also a strength of this
study, as to our knowledge previous investigations on
exercise in ALS had a maximum follow-up of 6 months.
Other study limitations to be addressed may come
from the selection of the exercises that may be not opti-
mal, and from treatment duration as a 10-week regimen
(although followed by continuation by the patient and
caregiver at home) may be not sufficient to determine the
effect of exercise.
In conclusion, our study showed that twice-a-week ses-
sions composed of a mixture of exercises may have the
same beneficial effect on the patient that a high-frequency
physical exercise programs, but further studies are war-
ranted to overcome our study limitations.
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